Pfizer to buy 8.1% of capital of vaccines company Valneva By Reuters



© Reuters. FILE PHOTO: A person walks past a Pfizer logo amid the coronavirus disease (COVID-19) pandemic in the Manhattan borough of New York City, New York, U.S., April 1, 2021. REUTERS/Carlo Allegri


PARIS (Reuters) – French specialty vaccine company Valneva and U.S. healthcare giant Pfizer (NYSE:) said they had entered an equity subscription agreement under which Pfizer will invest 90.5 million euros ($95.24 million) in Valneva, representing 8.1% of its capital.

The deal comes through a reserved capital increase to further support the strategic Lyme partnership between the two companies, they added in a statement.

($1 = 0.9502 euros)

Leave a Comment

Leading the way

Let's build a better world together

Project planning
Design expertise
Great qualifications

Nullam vestibulum finibus sapien, id consequat mauris tempus auctor.


90 Newport St., Natick, MA 01760

83 Taylor Street, Kings Mountain, NC 28086

22 Birch Hill St., Villa Rica, GA 30180

Support requests

Nullam scelerisque leo felis, quis congue mauris tristique in. Suspendisse pulvinar, felis eu facilisis mattis, turpis odio luctus nisi, et ultrices velit enim quis lacus.

Request a quote

[Insert your contact form here]


Vivamus vehicula dictum elit at bibendum. Etiam finibus eros ut urna auctor ullamcorper. Sed at erat eget nisl rutrum ultrices sed eu ex.


Sign up to receive the latest news and trends from our company.

More questions? Get in touch